Most mail-order pharmacies have a temperature excursion policy. What fewer have is packaging that makes that policy irrelevant.
USP General Chapter <1079.2> is not a suggestion. It applies to every entity that handles a finished drug product — manufacturers, wholesale distributors, third-party logistics providers, mail-order pharmacies, and anyone else with a hand in the supply chain. If your product leaves a temperature-controlled environment and gets shipped in a Styrofoam cooler with a gel pack, USP <1079.2> governs what happens when that cooler fails. And Styrofoam coolers fail.
The math is not forgiving.
Mean kinetic temperature (MKT) is the calculation method USP uses to evaluate whether a temperature excursion has compromised a drug product. It is not a simple average. MKT is derived from the Arrhenius equation — it accounts for the cumulative thermal stress a product experiences over time, and it weights higher temperatures more heavily than lower ones. A long, moderate excursion can be just as damaging as a short, severe one. The math does not care that your carrier was late because of weather.
For controlled cold temperature (CCT) products — the 2°–8°C range where most refrigerated pharmaceuticals live — the excursion window is narrow. USP allows a maximum excursion to 15°C, for no more than 24 hours, with an MKT not exceeding 8°C. Miss any one of those parameters and you have a nonconforming event that requires documented evaluation and justification. Every single time.
One excursion is a nonconforming event. Repeated excursions mean your system is out of control.
That is not ColdShip's language. That is USP's language, directly from <1079.2>: "A storage or transportation system that has repeated excursions should be considered a system out of control that needs to be corrected."
If your packaging is generating repeated excursions, you cannot MKT-calculate your way out of it. You cannot lower your warehouse temperature for a few days to offset the damage. Degradation from a high-temperature excursion is not reversible. USP is explicit on this point.
The packaging decision is a compliance decision.
Styrofoam performs inconsistently across climate zones, carrier handling conditions, and transit durations. It is a material designed for a different era of cold chain logistics, before mail-order pharmacy volumes, before last-mile delivery complexity, and before the regulatory scrutiny that comes with shipping refrigerated biologics and specialty medications directly to patients.
ColdShip packaging is validated to maintain temperature within CCT excursion thresholds across standard last-mile transit profiles, with lane-specific data available for warm, temperate, and cold climate zones. Switching documentation is structured to support your internal revalidation process and satisfy FDA, state board of pharmacy, and QA review.
The question is not whether your current packaging could generate a nonconforming excursion event. The question is whether you have documented evidence that it won't.
If you don't, that is the problem ColdShip solves.